P1, N=60, Recruiting, Zai Lab (Hong Kong), Ltd. | Active, not recruiting --> Recruiting | Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026

2 months ago

Enrollment open • Trial completion date • Trial primary completion date

Keytruda (pembrolizumab) • ZL-1218

5ms

KEYNOTE-F22: A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=60, Active, not recruiting, Zai Lab (Hong Kong), Ltd. | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed • Combination therapy • Metastases

Keytruda (pembrolizumab) • ZL-1218

almost2years

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=60, Recruiting, Zai Lab (Hong Kong), Ltd.

almost 2 years ago

New P1 trial • Combination therapy • Metastases

Keytruda (pembrolizumab) • ZL-1218

3years

ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells (AACR 2022)

We are currently exploring the significance of these distinct populations and the impact of ZL-1218-mediated depletion of both CCR8 high- and CCR8 low-expressing subsets in multiple indications. Together, these data support the advancement of ZL-1218 into clinical evaluation as a novel therapeutic candidate to treat human solid tumors.

3 years ago

PD(L)-1 Biomarker • IO biomarker

CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)

CCR8 expression

ZL-1218